Literature DB >> 19282158

Ultrasound imaging to assess inter- and intra-fraction motion during bladder radiotherapy and its potential as a verification tool.

C A McBain1, M M Green, J Stratford, J Davies, C McCarthy, B Taylor, D McHugh, R Swindell, V Khoo, P Price.   

Abstract

AIMS: Organ motion is the principle source of error in bladder cancer radiotherapy. The aim of this study was to evaluate ultrasound bladder volume measurement as a surrogate measure of organ motion during radiotherapy: (1) to assess inter- and intra-fraction bladder variation and (2) as a potential treatment verification tool.
MATERIALS AND METHODS: Twenty patients receiving radical radiotherapy for bladder cancer underwent post-void ultrasound bladder volume measurement at the time of radiotherapy treatment planning (RTP), and immediately before (post-void) and after receiving daily fractions.
RESULTS: Ultrasound bladder volume measurement was found to be a simple and acceptable method to estimate relative bladder volume changes. Six patients showed significant changes to post-void bladder volume over the treatment course (P<0.05). The mean inter-fraction post-void bladder volume of five patients exceeded their RTP ultrasound bladder volume by more than 50%. Intra-fraction bladder volume increased on 275/308 (89%) assessed fractions, with the mean intra-fraction volume increases of seven patients exceeding their RTP ultrasound bladder volume by more than 50%.
CONCLUSIONS: Both day-to-day bladder volume variation and bladder filling during treatment should be considered in RTP and delivery. Ultrasound may provide a practical daily verification tool by: supporting volume limitation as a method of treatment margin reduction; allowing detection of patients who may require interventions to promote bladder reproducibility; and identifying patients with prominent volume changes for the selective application of more advanced adaptive/image-guided radiotherapy techniques.

Entities:  

Mesh:

Year:  2009        PMID: 19282158     DOI: 10.1016/j.clon.2009.01.016

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer.

Authors:  Farshad Foroudi; Lesley Wilson; Mathias Bressel; Annette Haworth; Colin Hornby; Daniel Pham; Jim Cramb; Suki Gill; Keen Hun Tai; Tomas Kron
Journal:  Radiat Oncol       Date:  2012-07-23       Impact factor: 3.481

2.  Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers.

Authors:  Kentaro Nishioka; Shinichi Shimizu; Nobuo Shinohara; Yoichi M Ito; Takashige Abe; Satoru Maruyama; Norio Katoh; Rumiko Kinoshita; Takayuki Hashimoto; Naoki Miyamoto; Rikiya Onimaru; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2017-03-01       Impact factor: 3.481

3.  Cost-effective immobilization for whole brain radiation therapy.

Authors:  Ashley E Rubinstein; W Scott Ingram; Brian M Anderson; Skylar S Gay; Xenia J Fave; Rachel B Ger; Rachel E McCarroll; Constance A Owens; Tucker J Netherton; Kelly D Kisling; Laurence E Court; Jinzhong Yang; Yuting Li; Joonsang Lee; Dennis S Mackin; Carlos E Cardenas
Journal:  J Appl Clin Med Phys       Date:  2017-06-06       Impact factor: 2.102

4.  An ultrasound based platform for image-guided radiotherapy in canine bladder cancer patients.

Authors:  Justin T Sick; Nicholas J Rancilio; Caroline V Fulkerson; Jeannie M Plantenga; Deborah W Knapp; Keith M Stantz
Journal:  Phys Imaging Radiat Oncol       Date:  2019-11-15

5.  Comparison of Library of Plans with two daily adaptive strategies for whole bladder radiotherapy.

Authors:  Duncan den Boer; Mariska D den Hartogh; Alexis N T J Kotte; Jochem R N van der Voort van Zyp; Juus L Noteboom; Gijsbert H Bol; Thomas Willigenburg; Anita M Werensteijn-Honingh; Ina M Jürgenliemk-Schulz; Astrid L H M W van Lier; Petra S Kroon
Journal:  Phys Imaging Radiat Oncol       Date:  2021-11-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.